or Try an Advanced Search...

    Technical Analysis for ITOS - iTeos Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 10.80 1.89% 0.20
    ITOS closed up 1.89 percent on Friday, April 26, 2024, on 47 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 8
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical ITOS trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 1.89%
    200 DMA Resistance Bearish 2.18%
    Outside Day Range Expansion 2.18%
    Wide Bands Range Expansion 2.18%
    Pocket Pivot Bullish Swing Setup -1.73%
    NR7 Range Contraction -1.73%
    Inside Day Range Contraction -1.73%
    Older End-of-Day Signals for ITOS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 15 hours ago
    60 Minute Opening Range Breakout about 15 hours ago
    Rose Above 10 DMA about 17 hours ago
    10 DMA Resistance about 18 hours ago
    Up 2% about 18 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ITOS Chart by TradingView
    Basic chart:

    Profile

    Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Adenosine Therapeutics For Cancer

    Is ITOS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 7 iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
    Mar 6 Recap: ITeos Therapeutics Q4 Earnings
    Mar 6 iTeos Therapeutics GAAP EPS of -$0.85 beats by $0.18
    Mar 6 iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
    Mar 6 iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    Mar 5 iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
    Feb 26 Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
    Jan 10 iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
    Jan 8 iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones
    Jan 8 iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
    See more ITOS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.24
    52 Week Low 8.2
    Average Volume 299,411
    200-Day Moving Average 11.17
    50-Day Moving Average 11.37
    20-Day Moving Average 11.66
    10-Day Moving Average 10.82
    Average True Range 0.58
    RSI (14) 43.82
    ADX 18.05
    +DI 22.77
    -DI 29.72
    Chandelier Exit (Long, 3 ATRs) 12.07
    Chandelier Exit (Short, 3 ATRs) 11.74
    Upper Bollinger Bands 13.54
    Lower Bollinger Band 9.78
    Percent B (%b) 0.27
    BandWidth 32.22
    MACD Line -0.30
    MACD Signal Line -0.15
    MACD Histogram -0.1487
    Fundamentals Value
    Market Cap 386.48 Million
    Num Shares 35.8 Million
    EPS -1.75
    Price-to-Earnings (P/E) Ratio -6.17
    Price-to-Sales 5.87
    Price-to-Book 0.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.33
    Resistance 3 (R3) 11.30 11.10 11.24
    Resistance 2 (R2) 11.10 10.97 11.11 11.21
    Resistance 1 (R1) 10.95 10.88 11.03 10.98 11.18
    Pivot Point 10.75 10.75 10.79 10.76 10.75
    Support 1 (S1) 10.60 10.62 10.68 10.63 10.42
    Support 2 (S2) 10.40 10.53 10.41 10.39
    Support 3 (S3) 10.25 10.40 10.36
    Support 4 (S4) 10.28